{
    "root": "35476ad0-9dab-49ef-e063-6294a90ad48f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Bimzelx",
    "value": "20250516",
    "ingredients": [
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        },
        {
            "name": "GLYCINE",
            "code": "TE7660XO1C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15428"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32954"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "BIMEKIZUMAB",
            "code": "09495UIM6V",
            "drugbank_id": "https://go.drugbank.com/drugs/DB12917"
        }
    ],
    "indications": {
        "text": "bimzelx humanized interleukin-17a f antagonist indicated treatment : moderate severe plaque psoriasis ( pso ) adults candidates systemic therapy phototherapy . ( 1.1 ) adults active psoriatic arthritis ( psa ) . ( 1.2 ) adults active non-radiographic axial spondyloarthritis ( nr-axspa ) objective signs inflammation . ( 1.3 ) adults active ankylosing spondylitis ( ) . ( 1.4 ) adults moderate severe hidradenitis suppurativa ( hs ) . ( 1.5 )",
        "doid_entities": [
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "hidradenitis (DOID:2282)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2282"
            },
            {
                "text": "hidradenitis suppurativa (DOID:2280)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2280"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hidradenitis suppurativa",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_387"
            },
            {
                "disease": "severe plaque psoriasis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_247353"
            }
        ]
    },
    "contraindications": {
        "text": "prior treatment : ( 2.1 ) evaluate patients tuberculosis infection . test liver enzymes , alkaline phosphatase , bilirubin . complete age-appropriate vaccinations recommended current immunization guidelines . plaque psoriasis administer 320 mg subcutaneous injection weeks 0 , 4 , 8 , 12 , 16 , every 8 weeks thereafter . patients weighing 120 kg , consider dose 320 mg every 4 weeks week 16 . ( 2.2 ) psoriatic arthritis administer 160 mg subcutaneous injection every 4 weeks . ( 2.3 ) patients coexisting moderate severe plaque psoriasis , plaque psoriasis . ( 2.2 ) non-radiographic axial spondyloarthritis administer 160 mg subcutaneous injection every 4 weeks . ( 2.4 ) ankylosing spondylitis administer 160 mg subcutaneous injection every 4 weeks . ( 2.5 ) hidradenitis suppurativa administer 320 mg subcutaneous injection week 0 , 2 , 4 , 6 , 8 , 10 , 12 , 14 16 , every 4 weeks thereafter . ( 2.6 ) full prescribing information recommendations regarding missed doses , preparation instructions . ( 2.7 , 2.8 , 2.9 )",
        "doid_entities": [
            {
                "text": "tuberculosis (DOID:399)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_399"
            },
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "hidradenitis (DOID:2282)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2282"
            },
            {
                "text": "hidradenitis suppurativa (DOID:2280)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2280"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe plaque psoriasis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_247353"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )",
    "contraindications_original": "Prior to treatment: ( 2.1 ) Evaluate patients for tuberculosis infection. Test liver enzymes, alkaline phosphatase, and bilirubin. Complete all age-appropriate vaccinations as recommended by current immunization guidelines. Plaque Psoriasis Administer 320 mg by subcutaneous injection at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing 120 kg or more, consider a dose of 320 mg every 4 weeks after Week 16. ( 2.2 ) Psoriatic Arthritis Administer 160 mg by subcutaneous injection every 4 weeks. ( 2.3 ) For patients with coexisting moderate to severe plaque psoriasis, use the dosage and administration for plaque psoriasis. ( 2.2 ) Non-Radiographic Axial Spondyloarthritis Administer 160 mg by subcutaneous injection every 4 weeks. ( 2.4 ) Ankylosing Spondylitis Administer 160 mg by subcutaneous injection every 4 weeks. ( 2.5 ) Hidradenitis Suppurativa Administer 320 mg by subcutaneous injection at Week 0, 2, 4, 6, 8, 10, 12, 14 and 16, then every 4 weeks thereafter. ( 2.6 ) See full prescribing information for recommendations regarding missed doses, preparation and administration instructions. ( 2.7 , 2.8 , 2.9 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Bimzelx",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        }
    ]
}